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Abstract Patients with highly active relapsing-remitting
multiple sclerosis (RRMS) are at greater risk for disease
progression and may respond differently to MS therapeutics
than those with less active disease. The current post hoc
analysis evaluated the effects of daclizumab high-yield pro-
cess (DAC HYP) vs. placebo in patients with highly active
RRMS in the SELECT study. Highly active RRMS was
defined as patients with C2 relapses in the year before ran-
domization and C1 gadolinium-enhancing (Gd?) lesion at
baseline. Because results were similar in the DAC HYP dose
groups, data from the DAC HYP arms were pooled for ana-
lysis. Treatment with DAC HYP resulted in similar effects in
highly active (n = 88) and less active (n = 506) RRMS
patients. DAC HYP reduced the annualized relapse rate by
50 % and 51 % in the highly active (p = 0.0394) and less
active (p \ 0.0001) groups vs. placebo, respectively (inter-
action p = 0.82). DAC HYP reduced new/newly-enlarging
T2 lesions (highly active RRMS 76 % reduction, p \ 0.0001;
less active RRMS 73 % reduction, p \ 0.0001; interaction
p = 0.18), the risk of having more Gd? lesions (highly active
RRMS 89 % reduction, p \ 0.0001; less active RRMS 86 %
reduction, p \ 0.0001; interaction p = 0.46), and sustained
disability progression (highly active RRMS 88 % reduction,
p = 0.0574; less active RRMS 46 % reduction, p = 0.0383;
interaction p = 0.22) vs. placebo. DAC HYP efficacy was
similar across the spectrum of MS disease activity as assessed
prior to treatment initiation.
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Introduction
Multiple sclerosis (MS) is characterized by focal demye-
lination and axonal degeneration within the central nervous
system, and subtypes of MS are classified according to the
course and stage of disease. Approximately 85 % of
patients with MS initially present with a clinically isolated
syndrome that evolves into relapsing-remitting MS
(RRMS), and eventually secondary progressive MS [1].
However, there is considerable variability in the clinical
course of disease within those subtypes. Some patients with
RRMS experience slow onset of secondary progressive MS
over a period of more than 20 years, whereas others
experience more severe symptoms and rapid evolution of
MS within a few years of diagnosis [1, 2]. Several studies
have shown that the frequency of relapses, the presence of
gadolinium-enhancing (Gd?) lesions and T2 lesion burden
early in the course of MS are predictors for more rapid
progression of disability [2–7].
The potential benefits of immunomodulatory therapy in
patients with RRMS may be especially important for those
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with highly active RRMS. Highly active RRMS is some-
times known as rapidly evolving severe RRMS, defined by
the European Medicines Agency as patients who have at
least two disabling relapses in one year and at least one Gd?
lesion on brain magnetic resonance imaging (MRI) or a
significant increase in T2 lesion load compared with a
previous recent MRI [8, 9]. More frequent relapses and MRI
lesion activity early in the course of MS have been asso-
ciated with greater risk of long-term disability progression
[3, 4, 6, 7]. Therefore, it is important to assess the efficacy
of new MS therapies in this high-risk subgroup.
Daclizumab is a humanized monoclonal antibody spe-
cific for CD25 (the a subunit of the high-affinity interleu-
kin-2 receptor) that is currently being evaluated as a
potential treatment for RRMS [10]. The phase II CHOICE
study demonstrated that the addition of daclizumab to
interferon beta (IFNb) therapy significantly reduced new or
newly-enlarging lesions on brain MRI in patients with
RRMS who experienced MS disease activity while on
IFNb monotherapy [11]. More recently, the SELECT study
randomized patients with RRMS (n = 621) to treatment
with subcutaneous daclizumab high-yield process (DAC
HYP) 150 mg, DAC HYP 300 mg or placebo every
four weeks for 52 weeks [12]. In that study, DAC HYP
monotherapy significantly reduced the annualized relapse
rate (ARR) and new brain MRI lesion activity, and slowed
disability progression in patients with RRMS [12]. The
objective of this analysis was to evaluate the efficacy of
DAC HYP in patients in the subgroup with highly active
RRMS prior to enrollment in the SELECT study.
Materials and methods
Study design
Details of the methods of the SELECT study have been
published [12]. Briefly, 621 patients with RRMS were ran-
domized to treatment with DAC HYP 150 mg, DAC HYP
300 mg or placebo administered subcutaneously every
four weeks for 52 weeks. Eligible patients were
18–55 years of age with RRMS (2005 McDonald criteria)
[13] and a baseline Expanded Disability Status Scale (EDSS)
score of 0–5.0 [14]. Patients were required to have had at
least one confirmed MS relapse within 12 months prior to
randomization or one new Gd? lesion on brain MRI per-
formed within six weeks prior to randomization. Patients
were excluded if they had primary-progressive, secondary-
progressive or progressive-relapsing MS. The primary effi-
cacy endpoint in SELECT was the ARR. Secondary and
tertiary outcomes included the effect of DAC HYP vs. pla-
cebo on the number of new or newly-enlarging T2-hyper-
intense lesions at week 52 vs. baseline, the number of Gd?
lesions at week 52 vs. baseline and three-month confirmed
disability progression. The SELECT study [12] was con-
ducted in compliance with the ethical principles of Good
Clinical Practice, according to the International Conference
on Harmonisation Harmonised Tripartite Guideline and the
ethical principles outlined in the Declaration of Helsinki.
Institutional review board/ethics committee approval was
obtained at each participating center and patients provided
written informed consent at the time of enrollment.
Patients
Highly active RRMS was defined as at least two relapses in
the year prior to randomization and at least one Gd? lesion
at baseline, all other patients comprised the less active
RRMS subgroup [15, 16]. Efficacy analyses were evaluated
in a subset of the intent-to-treat (ITT) population who had
nonmissing baseline MRI data. The ITT population inclu-
ded all patients who underwent randomization (except for
21 patients from a single study center who were prospec-
tively excluded from the ITT population owing to detection
of systematic misdosing at that center during study moni-
toring). To be consistent with the efficacy analyses, the
safety analyses were evaluated in all randomized patients
who had MRI data at baseline. Safety data for all patients
in SELECT have been published [12]. Because the efficacy
outcomes were similar between the DAC HYP 150 mg and
300 mg groups in SELECT [12], data for both DAC HYP
treatment groups were pooled for this analysis.
Assessments
ARR, time to three-month confirmed disability progression,
the risk of having more Gd? lesions at week 52 and the
number of new or newly-enlarging T2-hyperintense lesions
between weeks 0 and 52 were evaluated for DAC HYP vs.
placebo in both the highly active RRMS and less active
RRMS subgroups. Relapses were defined as new or recurrent
neurologic symptoms that were not associated with fever or
infection and which lasted 24 h or more, accompanied by
new neurologic findings on assessment by the examining
neurologist. An independent committee consisting of MS
neurologists blinded to the treatment group adjudicated
whether the definition of MS relapse was met. MRI scans
were performed for all patients at weeks 24, 36 and 52.
Disability progression was defined as at least a 1.0-point
increase in EDSS score that was sustained for 12 weeks for
patients with a baseline EDSS score of 1.0 or more or at least
a 1.5-point increase for patients whose baseline EDSS score
was 0. EDSS score was evaluated every 12 weeks and at
weeks 20, 52, 60 and 72 as well as at unscheduled relapse
visits. Confirmation of disability progression could not take
place at a visit when a relapse was occurring.
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Statistical analyses
For each efficacy outcome, the percent reduction and 95 %
confidence intervals (CIs) for DAC HYP vs. placebo were
estimated in each disease activity subgroup. The ARR was
estimated from a negative binomial regression model adjusted
for treatment and the number of relapses in the year prior to
study entry. The odds ratio for comparison between the DAC
HYP and placebo groups of having more Gd? lesions at week
52 was evaluated based on an ordinal logistic regression model
adjusted for baseline Gd? lesions and treatment. The mean
number of new or newly-enlarging T2-hyperintense lesions
between weeks 0 and 52 was estimated from a negative
binomial regression model adjusted for treatment and the
number of T2 lesions at baseline. The estimated time to pro-
gression and proportion of patients with progression was cal-
culated based on the Kaplan–Meier product limit method. The
hazard ratio and p-value assessing the difference between the
treatment groups were estimated from a Cox proportional
hazards model controlling for baseline EDSS score (B2.5 vs.
[2.5). p-values for the interaction were derived in separate
models that also adjusted for baseline, treatment and MS dis-
ease activity (highly active RRMS vs. less active RRMS) by
treatment variable interaction.
Results
The demographic and clinical characteristics for all ran-
domized patients with baseline MRI data (n = 615;
Table 1) by disease activity subgroup and treatment are
shown Table 1. As would be expected, relapse and MRI
lesion activity were higher in patients with highly active
RRMS compared with those with less active RRMS.
Among the ITT population with MRI data at baseline
(n = 594), 88 patients met the criteria for highly active
RRMS (placebo, n = 30 [15 % of placebo]; DAC HYP,
n = 58 [15 % of pooled DAC HYP]), whereas 506 patients
were categorized with less active RRMS (placebo,
n = 165; pooled DAC HYP, n = 341). In patients in the
placebo group, on-study ARR was 50 % higher in patients
with highly active RRMS compared with those with less
active RRMS (Fig. 1). Similarly, in placebo-treated
patients, the mean number of new Gd? lesions and the
mean number of new or newly-enlarging T2 lesions
between weeks 0 and 52 was much greater in patients with
highly active RRMS vs. less active RRMS (Fig. 1).
DAC HYP was associated with significant improvements
in clinical and radiologic outcomes among patients with
highly active RRMS. After one year of DAC HYP treatment,
the ARR was reduced by 50 % in patients with highly active
RRMS (95 % CI 5–74 %; p = 0.0394) and by 51 % in those
with less active RRMS (95 % CI 32–65 %; p \ 0.0001
[interaction p-value, p = 0.82]; Fig. 2) vs. placebo. DAC
HYP treatment had significant effects on brain lesion activity
on MRI in both disease activity subgroups. In patients with
highly active RRMS, treatment with DAC HYP reduced the
risk of having more Gd? lesion activity at week 52 by 89 %
(95 % CI 72–96 %; p \ 0.0001) vs. placebo in the highly
active RRMS subgroup and by 86 % (95 % CI 78–91 %;
Table 1 Demographic and baseline clinical characteristics
Less active RRMS Highly active RRMS
Placebo (n = 173) DAC HYP (n = 351) Placebo (n = 30) DAC HYP (n = 61)
Demographics
Age, years, mean (SD) 36.5 (9.2) 35.6 (8.7) 37.0 (8.4) 33.0 (9.0)
Sex, female (%) 62 67 67 62
Race, white (%) 97 96 93 98
MS disease characteristics
No prior approved RRMS therapy (%)a 88 84 80 74
Years since MS diagnosis, mean (median) 4.2 (5.3) 4.1 (4.4) 3.7 (5.2) 4.1 (5.5)
Number of relapses in past year, mean (SD) 1.2 (0.5) 1.2 (0.6) 2.2 (0.5) 2.3 (0.7)
Baseline EDSS score, mean (SD) 2.8 (1.2) 2.7 (1.2) 2.5 (1.1) 3.0 (1.3)
MRI brain lesions
C1 Gd? lesion (%) 35 34 100 100
Number of Gd? lesions, mean (SD) 1.5 (4.4) 1.3 (2.9) 4.4 (4.4) 4.3 (4.6)
Number of T2-hyperintense lesions, mean (SD) 36.9 (29.9) 37.0 (31.3) 54.2 (40.5) 58.6 (36.8)
Volume of T2-hyperintense lesions, mean (SD) 7,245.7 (8,623.0) 7,656.0 (9,299.8) 12,893.3 (12,214.1) 12,987.1 (11,360.9)
RRMS relapsing-remitting multiple sclerosis, DAC HYP daclizumab high-yield process, SD standard deviation, MS multiple sclerosis, EDSS
Expanded Disability Status Scale, MRI magnetic resonance imaging, Gd? gadolinium-enhancing
a Patients who had no prior use of approved RRMS treatments (interferon beta-1a, interferon beta-1b, natalizumab, glatiramer acetate or
mitoxantrone)
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p \ 0.0001) in the less active RRMS subgroup (interaction
p-value, p = 0.46; Fig. 3). Moreover, the number of new or
newly-enlarging T2-hyperintense lesions between weeks 0
and 52 was reduced by 76 % (95 % CI 60–85 %;
p \ 0.0001) in patients with highly active RRMS and by
73 % (95 % CI 63–80 %; p \ 0.0001) in those with less
active RRMS (Fig. 4) for DAC HYP treatment compared











































































































Fig. 1 On-study disease activity in patients treated with placebo, by
disease activity subgroup. Highly active RRMS was defined as at least
two relapses in the year prior to randomization and at least one Gd?
lesion at baseline, all other patients comprised the less active RRMS
subgroup. RRMS relapsing-remitting multiple sclerosis, ARR annual-
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Fig. 2 Adjusted ARR and upper 95 % CIs for patients with highly
active RRMS or less active RRMS at baseline and treated with DAC
HYP or placebo. Highly active RRMS was defined as at least two
relapses in the year prior to randomization and at least one
gadolinium-enhancing lesion at baseline, all other patients comprised
the less active RRMS subgroup. CI confidence interval, DAC HYP
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Fig. 3 The mean number of new Gd? lesions between weeks 0 and
52 and upper 95 % CIs for patients with highly active RRMS or less
active RRMS who were treated with DAC HYP or placebo. Highly
active RRMS was defined as at least two relapses in the year prior to
randomization and at least one Gd? lesion at baseline, all other
patients comprised the less active RRMS subgroup. p-values and
percentage reduction were estimated from an ordinal logistic regres-
sion model adjusted for baseline lesion count in each disease activity
subgroup. CI confidence interval, DAC HYP daclizumab high-yield
process, Gd? gadolinium-enhancing, RRMS relapsing-remitting
multiple sclerosis. a Percentage reductions represent the reduction
over placebo in the risk of having greater Gd? lesion activity
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Three-month confirmed disability progression was
observed in 1.8 % (n = 1) of DAC HYP-treated patients
vs. 13.8 % (n = 4) of placebo-treated patients in the highly
active RRMS subgroup and in 7.6 % (n = 24) of DAC
HYP-treated patients vs. 13.3 % (n = 21) of placebo-
treated patients in the less active RRMS subgroup. Treat-
ment with DAC HYP reduced the three-month confirmed
disability progression by 88 % (95 % CI -7 to 99 %;
p = 0.0574) in the highly active RRMS subgroup and by
46 % (95 % CI 3–70 %; p = 0.0383) in the less active
subgroup compared with placebo (interaction p-value,
p = 0.22; Fig. 5).
Similar to what was observed across the treatment
groups in the overall patient population in the SELECT
study [12], infections, cutaneous events and elevations of
liver enzymes, defined as elevations of alanine amino-
transferase/aspartate aminotransferase greater than five
times the upper limit of normal (59 ULN), occurred more
frequently with pooled DAC HYP treatment than with
placebo treatment in both the highly active RRMS and less
active RRMS subgroups (Table 2). In the current analysis,
the proportion of patients with any adverse event (AE) was
similar among the disease activity and treatment groups
(Table 2). Infections, cutaneous events and elevations of
liver enzymes greater than 59 ULN occurred with similar
frequency in DAC HYP-treated patients with highly active
RRMS and less active RRMS (Table 2). The most common
AEs (i.e., occurring in C10 % of any disease activity and
treatment group), excluding MS relapse, were nasophar-
yngitis, headache, upper respiratory tract infection and
paraesthesias (Table 2).
Discussion
In patients with highly active RRMS, treatment with DAC
HYP reduced the ARR by 50 % (95 % CI 5–74 %) com-
pared with placebo. This robust effect on relapse rate
reduction in patients with highly active RRMS was consis-
tent with the treatment effect of DAC HYP vs. placebo on
other key endpoints in this subgroup, such as new T2 lesions
(76 % reduction; 95 % CI 60–85 %) and disability pro-
gression (88 % reduction; 95 % CI -7 to 99 %). There was
no evidence in this analysis that disease activity at baseline
modified the effect of DAC HYP on MS activity as treatment
effects were similar in both the highly active RRMS and less
active RRMS subgroups for all examined endpoints.
There is accumulating evidence for the categorization of
patients with highly active RRMS as a clinically mean-
ingful subgroup. Clinical and radiologic evidence of dis-
ease activity, including the frequency of relapses [3, 4], a
high T2 lesion burden [6] or the presence of Gd? lesions
[7] early in the course of MS has been linked to a greater
risk of progression of disability over the long term. Addi-
tionally, the degree of recovery from the first relapse, time
from MS onset to the second neurologic episode and time
from MS onset to assignment of an EDSS score of 4.0
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Fig. 4 The adjusted mean number of new or newly-enlarging T2-
hyperintense lesions between weeks 0 and 52 and upper 95 % CIs for
patients with highly active RRMS or less active RRMS who were
treated with DAC HYP or placebo. Highly active RRMS was defined
as at least two relapses in the year prior to randomization and at least
one gadolinium-enhancing lesion at baseline, all other patients
comprised the less active RRMS subgroup. CI confidence interval,
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Fig. 5 Proportion of patients with three-month confirmed disability
progression in patients with highly active RRMS or less active RRMS
for DAC HYP vs. placebo. Highly active RRMS was defined as at
least two relapses in the year prior to randomization and at least one
gadolinium-enhancing lesion at baseline, all other patients comprised
the less active RRMS subgroup. CI confidence interval, DAC HYP
daclizumab high-yield process, RRMS relapsing-remitting multiple
sclerosis. a p-values and percentage reduction for DAC HYP vs.
placebo were estimated from a Cox proportional hazards model
controlling for baseline EDSS (B2.5 vs.[2.5) in each disease activity
subgroup
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irreversible disability [3]. In the current study, differences
were observed in on-study relapse activity, the mean
number of new Gd? lesions and the mean number of new
or newly-enlarging T2 lesions between the highly active
RRMS and less active RRMS subgroups of patients in the
placebo group (Fig. 1). While patients with highly active
RRMS may require an MS treatment with greater efficacy,
it is less clear whether in general they are more likely to be
refractory to such MS therapies. Previous studies of both
natalizumab and fingolimod have also reported mainte-
nance of efficacy in this subgroup of patients [15, 16].
Nevertheless, even when treatment efficacy is preserved on
a relative basis, the actual accumulation of inflammatory
pathology may be higher in this subgroup of patients with
MS over time and confer an increased risk for disease
progression.
As highly active RRMS is defined by the frequency of
relapses and Gd? lesions, its presence is likely a correlate
of the patient’s inflammatory burden of MS. Because
daclizumab modulates the immune system by inhibition of
high-affinity interleukin-2 signaling [17], we initially
hypothesized that DAC HYP may be more effective in
patients with highly inflammatory MS. It was notable that
treatment efficacy on relapses and MRI lesion activity
appeared nearly identical in the subgroups of patients with
highly active RRMS and those with less active RRMS. It is
plausible that the immunologic effects of daclizumab such
as CD56bright natural killer cell expansion [18], inhibition
of dendritic cell priming of T cells [19], and a decrease in
lymphoid tissue-inducer cells [20] may have efficacy in
MS independently of traditional measures of MS-related
inflammation. With the caveat that the subgroup sizes were
relatively small, it is interesting to note that DAC HYP
appeared to have a greater benefit on disability progression
in the highly active RRMS subgroup compared with the
less active RRMS subgroup. This finding is consistent with
the potential for DAC HYP to prevent permanent damage
to the central nervous system.
There are limitations to the current analysis. Since the
definition of highly active RRMS was based on the patient-
reported history of relapse, we could not directly assess
whether the relapses had been disabling, as indicated in
some definitions of highly active RRMS [8, 9]. Addition-
ally, we could not directly evaluate whether historic
relapses occurred while the patient had been treated with a
disease-modifying therapy. Thus, we could not determine
whether the highly active RRMS subgroup also had evi-
dence of being refractory to other MS treatments. How-
ever, clear differences in MS disease activity between
placebo-treated patients characterized at baseline as highly
active or less active indicated the characterization used in
this analysis accurately reflected patients’ risk for incident
MS-disease activity (Fig. 1). Finally, because this was a
post hoc analysis of the SELECT trial and owing to the
relatively small subgroup sample sizes, the results should
be confirmed independently.
Since patients with highly active RRMS are at higher
risk for disease progression, these patients may have dif-
ferent risk-benefit considerations for MS therapies, and it is
important to evaluate the performance of MS treatments in
this subgroup of patients. Further refinement of MS sub-
types and prognostic markers may improve the ability to
individualize therapeutic decision making for this group of
patients. The ongoing three-year phase III trial of DAC
HYP consisting of 1,800 patients (DECIDE: ClinicalTri-
als.gov identifier NCT01064401) will further inform on the
potential of DAC HYP as a treatment option for this high-
risk subgroup of the MS population.
Table 2 AEs by disease activity and treatment group
Less active RRMS Highly active RRMS
Placebo (n = 173) DAC HYP (n = 351) Placebo (n = 30) DAC HYP (n = 61)
Any AE, n (%) 136 (79) 258 (74) 25 (83) 49 (80)
Infections 77 (45) 183 (52) 12 (40) 32 (52)
Cutaneous events 25 (14) 72 (21) 2 (7) 11 (18)
Elevation of ALT/AST [59 ULN 1 (\1) 14 (4) 0 3 (5)
Most common AEs, n (%)a,b
Nasopharyngitis 27 (16) 50 (14) 4 (13) 10 (16)
Headache 18 (10) 33 (9) 3 (10) 7 (11)
Upper respiratory infection 12 (7) 32 (9) 2 (7) 8 (13)
Paraesthesia 7 (4) 8 (2) 3 (10) 1 (2)
AE adverse event, RRMS relapse-remitting multiple sclerosis, DAC HYP daclizumab high-yield process, ALT alanine aminotransferase, AST
aspartate aminotransferase, 59 ULN five times the upper limit of normal [12]
a Excluding multiple sclerosis relapse
b AEs that occurred in C10 % of patients in any disease activity and treatment group
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